The Breast Recurrence Score® test predicts both chemotherapy benefit and lack of benefit1,2
Only the Breast Recurrence Score test predicts who may, or may not, benefit from chemotherapy, regardless of clinical risk status.1,2,4,5,7
NSABP B-202
TAILORx1
MammaPrint did not show prediction of chemotherapy benefit in the MINDACT study6
MammaPrint may lead to overtreatment or undertreatment based on its risk classification result.
Patients randomized to chemotherapy (intent-to-treat)
Identified as MammaPrint Low Risk and clinical High Risk
Patients showed a trend toward chemotherapy benefit (31% risk reduction)5-year DMFS 95.7 vs 93.2 (CT vs no CT), P = ns
Adjusted HR: 0.69 (95% CI, 0.39, 1.21)
Identified as MammaPrint High Risk and clinical Low Risk
Patients did not receive a benefit chemotherapy5-year DMFS 96.0 vs 95.1 (CT vs no CT)
Adjusted HR: 1.09 (95% CI, 0.54, 2.19)
MammaPrint categorizes a substantially larger number of patients as high risk compared with the Oncotype DX Breast Recurrence Score test8
MammaPrint has poor agreement (74%) with the Breast Recurrence Score test in patient risk stratification8
Low Risk (-1 in 4 patients (n=70/247) potentially overtreated8
High Risk (-1 in 4 patients (n=6/50) potentially overtreated8
See why the Breast Recurrence Score test rises above
*MammaPrint has not shown proof of prediction of chemotherapy benefit.
MammaPrint is a registered trademark of Agendia, Inc. MammaPrint is a registered trademark of Agendia BV. Please refer to this manufacturer directly for more information.
-
References
Use our online physician portal
Order tests, access results, receive updates, and more in one place.
Sign up now